Dalbavancin: a new option for systemic treatment of Gram-positive endogenous endophthalmitis?

J Antimicrob Chemother. 2023 Dec 1;78(12):3005-3006. doi: 10.1093/jac/dkad308.
No abstract available

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Endophthalmitis* / drug therapy
  • Gram-Positive Bacteria
  • Gram-Positive Bacterial Infections* / drug therapy
  • Humans
  • Teicoplanin / therapeutic use

Substances

  • dalbavancin
  • Teicoplanin
  • Anti-Bacterial Agents